MedPath

ICM Co. Ltd.

🇰🇷South Korea
Ownership
Holding
Employees
-
Market Cap
-
Website
https://icm-bio.com

A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo

Conditions
Osteoarthritis, Knee
Interventions
Genetic: ICM-203
Drug: Placebo
First Posted Date
2023-03-02
Last Posted Date
2024-10-14
Lead Sponsor
ICM Co. Ltd.
Target Recruit Count
16
Registration Number
NCT05752032
Locations
🇦🇺

Barwon Health, Geelong, Victoria, Australia

🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.

Phase 1
Not yet recruiting
Conditions
Osteoarthritis, Knee
Interventions
Genetic: ICM-203
First Posted Date
2022-07-12
Last Posted Date
2025-05-01
Lead Sponsor
ICM Co. Ltd.
Target Recruit Count
18
Registration Number
NCT05454566
© Copyright 2025. All Rights Reserved by MedPath